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Abstract: Therapeutic options for right ventricular (RV) dysfunction and failure are strongly limited. 
Right heart failure (RHF) has been mostly addressed in the context of pulmonary arterial hypertension 
(PAH), where it is not possible to discern pulmonary vascular- and RV-directed effects of therapeutic 
approaches. In part, opposing pathomechanisms in RV and pulmonary vasculature, i.e., regarding apoptosis, 
angiogenesis and proliferation, complicate addressing RHF in PAH. Therapy effective for left heart failure 
is not applicable to RHF, e.g., inhibition of adrenoceptor signaling and of the renin-angiotensin system 
had no or only limited success. A number of experimental studies employing animal models for PAH or 
RV dysfunction or failure have identified beneficial effects of novel pharmacological agents, with most 
promising results obtained with modulators of metabolism and reactive oxygen species or inflammation, 
respectively. In addition, established PAH agents, in particular phosphodiesterase-5 inhibitors and soluble 
guanylate cyclase stimulators, may directly address RV integrity. Promising results are furthermore derived 
with microRNA (miRNA) and long non-coding RNA (lncRNA) blocking or mimetic strategies, which 
can target microvascular rarefaction, inflammation, metabolism or fibrotic and hypertrophic remodeling 
in the dysfunctional RV. Likewise, pre-clinical data demonstrate that cell-based therapies using stem or 
progenitor cells have beneficial effects on the RV, mainly by improving the microvascular system, however 
clinical success will largely depend on delivery routes. A particular option for PAH is targeted denervation 
of the pulmonary vasculature, given the sympathetic overdrive in PAH patients. Finally, acute and durable 
mechanical circulatory support are available for the right heart, which however has been tested mostly in 
RHF with concomitant left heart disease. Here, we aim to review current pharmacological, RNA- and 
cell-based therapeutic options and their potential to directly target the RV and to review available data for 
pulmonary artery denervation and mechanical circulatory support. 
Keywords: Right ventricle; right heart failure (RHF); pulmonary arterial hypertension (PAH); remodeling; right 
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Introduction
Right ventricular (RV) dysfunction is associated with poor 
clinical outcomes (1) independent of the etiology (2). Yet, 
specific therapies that directly target right heart dysfunction 
are strongly limited. RV dysfunction and failure and its 
pharmacological therapy have been studied predominantly 
in the context of pulmonary arterial hypertension (PAH) 
(3,4), and less commonly in left heart diseases (5). 
Indeed, current clinical therapies for PAH mainly pursue 
a reduction of pressure overload via relaxation of the 
pulmonary vasculature (4), although some drugs appear 
to have additional anti-remodeling or anti-inflammatory 
effects. Whether therapies specifically targeting the RV 
provide substantial benefit compared to existing therapies (4) 
is unknown. Current heart failure treatment, which has 
been approved for and tested in patients with left heart 
failure (LHF), is less effective or in some instances even 
ineffective or harmful in the treatment of right heart failure 
(RHF), given the unique geometry, mechanics, metabolism, 
vascularity and response to pressure overload of the RV 
(6-9). The scope of this article is to summarize emerging 
therapies of RHF. We review established vasodilatory 
therapies for PAH with a distinct focus on their potential 
or confirmed direct RV effects. We also summarize novel, 
innovative pharmacological, cell-based and RNA-based 
strategies specifically addressing the RV. Finally, we address 
RV-directed therapies in etiologies of RHF other than 
PAH, thereby creating a new focus towards the RV in 
conditions dominated by failing left heart structures. RV 
dysfunction in the context of congenital heart disease (CHD) 
is covered elsewhere in this special issue (10). Moreover, the 
molecular mechanisms of RV dysfunction in PAH with a 
particular focus on the coronary vasculature, sex hormones, 
and glucose/lipid metabolism are reviewed elsewhere in this 
special issue (3). 
Non-approved pharmacotherapies 
Potential of approved pulmonary vasodilator therapeutics 
to target the RV myocardium
In patients with PAH it is difficult to discriminate between 
vascular and myocardial effects of any therapy—the gold 
standard for distinction is invasive pressure-volume loop 
assessment. Meta-analyses of clinical data suggest that 
the direct impact of established PAH medications on 
the myocardium is limited (11,12). In a number of trials 
phosphodiesterase-5 (PDE-5) inhibitors and endothelin 
receptor antagonists (ERAs) failed to be beneficial in patients 
with group 2 pulmonary hypertension (PH), in particular 
with heart failure with preserved ejection fraction (HFpEF) 
(13-16) (for main clinical study findings see Table 1). In 
contrast, PDE-5 inhibitors, stimulators of soluble guanylate 
cyclase (sGC) and prostacyclin analogues appear to exert 
advantageous effects on RV myocardium in preclinical 
models (for schematic overview see Figure 1) (34-36). The 
experimental model of pulmonary artery banding (PAB), 
Table 1 Main findings from clinical studies using pharmacotherapeutics with an emphasis on the RV
Drug
Mechanism of  
action
Study design/patient cohort/reference
Benefit on  
(number of patients) 
No benefit on  
(number of patients)
Using approved PAH therapeutics
Bosentan ETA Multicentre, randomized, placebo-controlled  
pilot trial/HFpEF-PH (15)
– Exercise capacity,  
hemodynamics (n=20) 
Macitentan ETA Multicentre, placebo-controlled, randomized phase 
II study/PH-LV dysfunction (16)
– Hemodynamics (n=60)
Sildenafil PDE5-inhibitor Multicentre, double-blind, placebo-controlled, 
parallel-group, randomized clinical trial/HFpEF (13)
– Exercise capacity  
(n=216) 
Single-centre randomized controlled  
trial/HFpEF-PH (14)
– Exercise capacity,  
hemodynamics (n=52)
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Table 1 (continued)
Drug
Mechanism of  
action
Study design/patient cohort (reference)
Benefit on  
(number of patients) 
No benefit on  
(number of patients)
Targeting adrenoceptors
Carvedilol β1-RA, α1-RA Single-centre, double-blind, randomized,  
controlled trial/PAH (18)
– Hemodynamics, RV  
function, exercise  
capacity (n=30)
Cohort study/systemic RV (19) Exercise capacity, RV 
function (n=8)
–
Single-arm open-label pilot study/PAH (18) RV function (n=6) –
Bisoprolol β1-RA Single-centre, randomized, placebo-controlled,  
crossover trial/PAH (20)
– Exercise capacity, RV 
function (n=16) 
Randomized, placebo-controlled, double blind,  
cross-over study/PAH (21)
– RV function (n=18) 
Targeting the renin-angiotensin-aldosterone system
Spironolactone Mineralo- 
corticoid-RA
Randomized, double-blind, placebo-controlled 
trial/PAH (22)
– Exercise capacity  
(n=199)
Captopril ACE inhibitor Observational study/PH (23) – Hemodynamics (n=4)
Observational study/PH (24) – Hemodynamics (n=7) 
Targeting energy metabolism
Dichloroacetate PDK inhibitor Open-label study/PAH (25) Hemodynamics, RV 
function (n=16) 
–
Ranolazine Sodium current and 
partial FAO inhibitor




Single-centre, randomized, placebo-controlled 
trial/PAH (27)
– Hemodynamics,  
RV function (n=12)
Targeting inflammation and oxidative stress
Tocilizumab IL-6-RA Open label study/PAH (28) – Hemodynamics (n=21)
Anakinra IL-1-RA Single-group, open-label phase IB/II pilot  
study/PAH (29)
HF symptoms (n=6) Exercise capacity, RV 
function (n=6) 




rhACE2 rhACE2 Open-label pilot study/PAH (31) Hemodynamics (n=5) –
Targeting tyrosine kinases
Imatinib TKI Randomized, double-blind, placebo-controlled 
pilot study/PAH (32)
Hemodynamics (n=42) Exercise capacity,  
hemodynamics (mPAP) 
(n=42)
Observational study (in combination with  




ACE, angiotensin converting enzyme; ASK1, apoptosis signal-regulating kinase 1; FAO, fatty acid oxidation; ETA, endothelin-1 receptor 
antagonist; HF, heart failure; IL, interleukin; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PDE,  
phosphodiesterase; PDK, pyruvate dehydrogenase kinase; PH, pulmonary hypertension; RA, receptor antagonist; rh, recombinant human; 
RV, right ventricle; TKI, tyrosine kinase inhibitor.
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Figure 1 Scheme demonstrating main points of action of pharmacotherapeutics directly targeting RV myocardium in RHF. Key mechanisms 
of action and corresponding main drugs are given. ACE2, angiotensin converting enzyme 2; AMPK, 5'-adenosine monophosphate-activated 
protein kinase; ECM, extracellular matrix proteins; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa-light-chain-
enhancer of activated B-cells; Nrf2, nuclear factor erythroid 2-related factor 2; PDE, phosphodiesterase; PDK, pyruvate dehydrogenase 
kinase; PGI2, prostacyclin; PPAR, peroxisome proliferator-activated receptor; sGC, soluble guanylate cyclase. This figure was created using 
Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; https://smart.servier.com.
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PDE-5 (inhibitor; sildenafil) 
sGC (stimulator; riociguat) 
PGI2 (analogue; iloprost) 
ACE2 (recombinant ACE2) 
PDK (inhibitor; dichloroacetate) 
PPARγ (agonist; pioglitazone) 
AMPK (activator; metformin) 
Nrf2 (activator; bardoxolone methyl, dimethylfumarate, OA-NO2) 
NF-κB/MAPK (inhibitor)
In addition to pre-clinical also clinical studies demonstrate benefit
which induces RV pressure overload independently of 
pulmonary artery (PA) remodeling, allows for investigation 
of RV-directed effects (37). In PAB models PDE-5 
inhibition with sildenafil prevented RV dysfunction and 
reversed RV fibrotic remodeling (34,36,38) (for experimental 
studies see Table 2). sGC stimulation with riociguat improved 
RV systolic function and reduced RV fibrosis without 
affecting RV hypertrophy (RVH) in PAB-exposed mice. 
Likewise, the prostacyclin analogue iloprost improved 
RV systolic function and exercise capacity, which was 
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Using approved PAH therapeutics
PDE-5, inhibition PAB,  
AC-shunt, rat
Sildenafil PAB: ↑RV systolic function, exercise  
capacity, RV fibrosis
x (38)
No effect: RVH, RV diastolic function
No effect in AC-shunt
PDE-5, inhibition PAB, rat Sildenafil ↓RV fibrosis x (34)
↑RV diastolic function
No effect: RV systolic function, exercise 
capacity
PDE-5, inhibition PAB, mouse Sildenafil ↑RV systolic function x (36)
No effect: RVH, RV fibrosis
Prostacyclin,  
analogue
SuHx, PAB,  
rat
Iloprost ↓RV fibrosis x (35)
↑Exercise capacity (SuHx), RV systolic  
function (SuHx)
No effect: PA remodeling, RV systolic 
function (PAB)
Soluble guanylate  
cyclase, activator






MCT, rat Arotinolol ↓RVH, RVSP (39)
β-adrenoceptor,  
blockade









↑ RV systolic function, exercise capacity 
(SuHx), survival (MCT)
No effect: RVSP, PA remodeling
β-adrenoceptor,  
blockade
MCT, rat Nebivolol ↓PA remodeling x (42)
↑RV systolic function
β-adrenoceptor,  
enhancement of  
signaling







A61603 ↓RV fibrosis x (44)
↑RV systolic function
No effect: PA remodeling
Table 2 (continued)
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PAB, mouse A61603 ↓Liver weight x (45)
↑RV systolic function, exercise capacity
No effect: RVH, RV fibrosis, RV diastolic 
function
Targeting the renin-angiotensin-aldosterone system
AT1 receptor,  
antagonism
MCT, rat Losartan ↓PVR, PA remodeling x (46)
↑RV diastolic function
No effect: RV contractility
AT1 receptor,  
antagonism
PAB, rabbit Losartan No effect: RVH, RV systolic function x (47)
Neprilysin, inhibition;  
AT1 receptor,  
antagonism
PAB, rat Sacubitril/ 
valsartan
↓RVH x (48)
↑RV systolic and diastolic function
ACE, inhibition PAB, rabbit Ramipril No effect: RVH, RV systolic function x (47)
AT1 receptor +  
mineralocorticoid  
receptor, antagonism
PAB, rat Losartan +  
eplerenone
No effect: RV systolic function, RV 
remodeling, survival
x (49)
ACE2 PAB, mouse ACE2 ↓RVH x (50)
↑RV systolic function
No effect: RV fibrosis
ACE2 MCT, rat ACE2 ↓RVH, PA remodeling x (51)
↑RV systolic function











Spironolactone HOX: ↓RVSP, RV fibrosis, PA remodeling (53)
MCT: ↓RVSP, PA remodeling, PVR
No effect: RV fibrosis, RV remodeling
Mineralocorticoid  
receptor, antagonism
MCT, rat Spironolactone ↓RVSP, PA remodeling, PVR (54)
Mineralocorticoid  
receptor, antagonism
SuHx, rat Eplerenone ↓PA remodeling, PVR (54,55)
Mineralocorticoid  
receptor, antagonism
SuHx, rat Spironolactone ↓RVH, RVSP, PVR (55)
AT1 receptor +  
mineralocorticoid  
receptor
PAB rats Losartan +  
eplerenone
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Eplerenone ↓RVH, RVSP, PA remodeling (56) 
PAB: No effect: RVH, RV fibrosis, RV systolic 
function
Targeting inflammation and oxidative stress
Nrf2, stimulation of  






↓RVSP, RVH, PA remodeling (57)
Nrf2, stimulation of  
activity and expression
HOX, mouse Oltipraz ↓RVH, PA remodeling (58)
SOD, SOD mimetic MCT, rat EUK 134 ↓RV fibrosis, RVH x (59)
↑ RV systolic function
NADPH-oxidase,  
decrease of  
expression and activity 
HOX, mouse Rosiglitazone ↓RVSP, PA remodeling (60)
Vascular ROS release, 
reduction; PASMCs  
proliferation, decrease 
HOX, mouse OA-NO2 ↓RVSP, RVH, PA remodeling (61)
MPO, inhibition SuHx, rat AZM198 ↓RVSP, RVH, PA remodeling (62)
NF-κB, inhibition PAB, rat E6446,  
Pyrrolidine  
dithiocarbamate
↓ RV fibrosis x (63)
↑ RV systolic function
No effect: RVH
ASK1, inhibition PAB, mouse; 
SuHx, MCT, 
rat




p38MAPK, inhibition PAB, HOX, 
mouse
PH797804 ↓RV fibrosis Increased: RV systolic function x (65)
TNF-alpha,  
antagonism





Etanercept ↓RVSP, PVR (67)
↑RV diastolic function




ERBF ↓RVSP, RVH, PA remodeling x (68)
↑RV systolic function
IL-1, receptor  
antagonism




MCT: ↓RVH, RVSP, PA remodeling (69)
HOX: no effect
Targeting energy metabolism 
PDK, inhibition PAB, MCT rat Dichloroacetate ↓RVH x (70)
↑RV systolic function
Table 2 (continued)
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PDK, inhibition MCT, rat Dichloroacetate ↓PA remodeling, RVH, mortality (72)
PDK, inhibition RV volume 
overload, pig
Dichloroacetate ↓RVH x (73)
↑RV contractile reserve
FAO, partial inhibition PAB, rat Trimetazidine, 
ranolazine
↓RVH, RV fibrosis x (74)
↑RV systolic function, exercise capacity
FAO, partial inhibition MCT, HOX rat Trimetazidine ↓RVSP, RVH, PA remodeling (75)




Metformin ↓RV lipid accumulation x (76)
No effect: RV systolic and diastolic function
RV lipid deposition,  
reduction
Western diet  
+ PAB, mouse
Metformin ↓RVSP, RVH x (77)
↑RV diastolic function
PPARγ activation,  
reduction of RV  
intramyocardial lipid 
deposition
SuHx, rat Pioglitazone ↓RVSP, RVEDP, RVH, RV fibrosis, PA  
remodeling 
x (78)
↑RV systolic function, RV diastolic function
PPARγ, activation ApoE-ko + 
HFD, mouse
Rosiglitazone ↓RVSP, RVH, PA remodeling x (79)
PPARγ, activation HOX, rat Rosiglitazone ↓RVSP, RVH, PA remodeling (80) 
PPARγ, activation MCT, rat Pioglitazone ↓RVSP, RVH, RV fibrosis, PA remodeling (81)
↑Survival
Targeting tyrosine kinases
Tyrosine kinase,  
inhibition 
MCT, rat,  
HOX, mouse
Imatinib ↓RVH, RVSP, PA remodeling (82)
Targeting extracellular matrix remodeling
Galectin-3, inhibition PAB, mouse N- 
acetyllactosamine
↓RV fibrosis x (83)
No effect: RV systolic function
Targeting HDACs
HDAC class I, II, IV,  
inhibition
HOX, rat Valproic acid,  
suberoylanilide
↓RVH, RVSP, PA remodeling (84)
HDAC class I,  
inhibition
HOX, rat MGCD0103 ↓RVSP, PA remodeling x (85)
No effect: RV systolic function
HDAC class I, II,  
inhibition
PAB, rat Trichostatin A,  
valproic acid
↓RV systolic function (86)
↑RV fibrosis
Table 2 (continued)
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HDAC class I,  
inhibition
MCT, rat Valproic acid ↓PA remodeling, RVH (87) 
HDAC class I, II,  
inhibition
SuHx, rat Trichostatin A No effect: PA remodeling, RV systolic  
function, RVSP, RVH
x (88)




Tubastatin A ↓PA remodeling, RVH, RVSP, PVR (89)
ACE, angiotensin-converting enzyme; ApoE-ko, apolipoprotein E-knockout; AT1, angiotensin II receptor type 1; HDAC, histone 
deacetylase; HFD, high fat diet; HOX, hypoxia; MCT, monocrotaline; Nrf2, nuclear factor erythroid 2-related factor 2; PDE-5, 
phosphodiesterase-5; PA, pulmonary artery; PAB, pulmonary artery banding; PVR, pulmonary vascular resistance; RV, right ventricle; RVH, 
right ventricular hypertrophy; RVSP, right ventricular systolic pressure; SuHx, Sugen5416/hypoxia.
surprisingly not associated with a reduction of PA pressure 
and RVH in the Sugen5416/hypoxia (SuHx) rat model for 
PAH. Rather, it was accompanied by a marked reduction 
of RV fibrosis, as it was seen also in PAB-exposed rats (35). 
These discrepant findings underline the difficulties 
in translating PAH medications to treatment of RHF 
originating from conditions other than PAH. Recently, 
sildenafil administration was evaluated for prevention of 
acute RHF following implantation of left ventricular assist 
device (LVAD). LVAD implantation is an important strategy 
in patients with end-stage LHF, however, in 4% to 50% of 
cases RHF occurs early after implantation and significantly 
increases mortality (90). Sildenafil is frequently used off-label 
to treat and/or prevent RHF post LVAD implantation (91). 
However,  a  recently published analysis  from the 
INTERMACS (Interagency Registry for Mechanically 
Assisted Circulatory Support) registry uncovered that the 
incidence of RHF and the relative risk of bleeding was 
markedly increased with sildenafil therapy compared to 
controls (17). These disappointing results question the 
benefit of PA vasodilators for LVAD recipients (clinical 
trial using sildenafil: NCT03356353) (for ongoing clinical 
trials, see Table 3). Other clinical studies will investigate 
the ERA macitentan for treatment of PH following LVAD 
implantation (NCT02554903), and the inotropic agents 
levosimendan (a calcium sensitizer) (NCT03659851) 
or milrinone (a PDE-3 inhibitor) (NCT03217331) as 
pretreatment before LVAD implantation. Given that both 
milrinone and levosimendan have additional PA vasodilating 
properties, they might be particularly well suited. 
Levosimendan was effective to restore RV-PA coupling in 
an experimental model of acute pressure overload (92) and 
is currently tested also in patients with HFpEF-associated 
PH (NCT03541603, NCT03624010). 
Further preclinical studies and careful evaluation of 
clinical data are required to follow up on the discrepancies 
of experimental and clinical studies, on the promising 
preclinical results and to unravel potential molecular 
mechanisms that may directly target RV dysfunction. 
Neurohormonal modulation
Beta-adrenoceptor antagonists
Use of beta-adrenoceptor antagonists (β-blocker) is an 
essential component of LHF therapy. In contrast, it is 
not clear whether β-blocker provide benefit for RHF, 
although at least for RHF secondary to PAH it is known 
that neurohormonal activation is high (93). Currently, 
β-blocker application is not recommended for PAH due 
to their negative inotropic and chronotropic effects. 
Clinical studies on the use of β-blockers in PAH had 
inconsistent results dependent on whether the β1-selective 
bisoprolol (20,21), or β1- and α1-blockade (carvedilol) was 
employed. Carvedilol was safe in PAH patients and even 
normalized pathologically increased RV glucose uptake 
in PAH (18). However, whereas it improved RV function 
and exercise capacity in small studies with PAH or RV 
dysfunction of other origin than PAH (19,94), no benefit on 
hemodynamics or exercise capacity was observed in a larger 
PAH study (18) (Table 1). Small clinical trials are ongoing 
for PAH (NCT02507011, NCT00240656) (Table 3). 
























































































Table 3 Ongoing clinical trials

















NCT03217331 CRD-102 for Right Heart Failure 











6 N/A 1 + 2 Completed –
NCT02554903 A Prospective, Multicenter,  
Double-blind, Randomized,  
Placebo-controlled, Parallel 
Group Study to Assess the  
Efficacy and Safety of  
Macitentan in Patients with  
Pulmonary Hypertension After 
Left Ventricular Assist Device 
Implantation
Macitentan ETA PH PVR 57 Randomized 2 Completed –
NCT03356353 Sildenafil for the Prevention of 
Right Heart Failure Following  
Continuous-Flow Left Ventricular 




End stage heart 
failure
PVR 24 N/A 3 Recruiting RHF
NCT03624010 Open-Label Rollover Study of  
Levosimendan in Patients with 
Pulmonary Hypertension with 
Heart Failure and Preserved Left 




HFpEF, PH, RHF Number 
of adverse 
events 
36 N/A 2 Active, not 
recruiting
–
NCT03659851 Pretreatment with  
Levosimendan In Patients  











NCT03541603 A Double-Blind, Randomized,  
Placebo-Controlled Study of  
Levosimendan in Pulmonary  
Hypertension Patients with 
Heart Failure and Preserved Left 



































































































































NCT00240656 Spironolactone Combined with 
Captopril and Carvedilol for 
the Treatment of Patients with 
Pulmonary Arterial  
Hypertension Associated with 
Congenital Heart Disease— 




















1 Completed RVAT, RVET, RVET/
RVAT
Targeting the renin-angiotensin-aldosterone system
NCT01712620 A Pilot Study of the Effect of  
Spironolactone Therapy on  
Exercise Capacity and  






70 Randomized 2 Recruiting RV function
NCT03344159 Spironolactone Therapy in 




PAH, PH, RV 
cardiomyopathy
NT-proBNP 40 Randomized 4 Suspended 
(COVID-19)
RV EF
NCT03177603 An Open-label, Dose-escalation 
Study to Evaluate the Safety,  
Tolerability, Pharmacokinetics 
and Pharmacodynamics of 
Single Doses of GSK2586881 









NCT03177603 A Dose-escalation Study in 




rhACE2 PAH PVR, CO, 
mPAP
23 Open label 2 Completed –
Targeting energy metabolism
NCT03629340 Phase II Trial of Metformin for  
Pulmonary Hypertension in Heart 













































































































Main RV  
function-specific 
endpoints
NCT03617458 Interventions Against Insulin  










39 Randomized 2 Recruiting TAPSE, RVEF, 
RVFA, RV  
longitudinal  
strain
NCT01083524 A Phase I, Open-Label, Two 
Centre Study to Evaluate  
Dichloroacetate (DCA) in  











1 Completed RV size/function
Targeting inflammation and oxidative stress
NCT02036970 A Dose-Ranging Study of the  
Efficacy and Safety of  







PAH, PH Walk  
distance
166 Randomized 2 Completed –
NCT02657356 A Study of the Efficacy and 
Safety of Bardoxolone Methyl in 














202 Randomized 3 Terminated 
(COVID-19)
–
NCT03068130 An Extended Access Program to 
Assess Long-term Safety of  









414 N/A 3 Recruiting –
NCT03449524 Phase 2 Multicenter,  
Double-Blind, Placebo  
Controlled, Efficacy, Safety, 
and Pharmacokinetic Study of 
2 Doses of CXA-10 on Stable 
Background Therapy in Subjects 






























































































































Main RV  
function-specific 
endpoints
NCT03738150 A Phase 2a Single-Arm, 
Open-Label, Multicenter  
Exploratory Study to Assess the 
Effects of Sotatercept (ACE-011) 
for the Treatment of Pulmonary 
Arterial Hypertension










25 N/A 2 Recruiting –
Targeting miRNA
NCT04045405 Phase I, Randomized,  
Double-blind, Placebo- 
controlled Study to Assess  
Safety, PK and PD Parameters 
of CDR132L in Patients with 








28 Randomized 1 Completed –
NCT03603431 A Phase 1, Randomized,  
Double-blind, Placebo- 
controlled, Single and Multiple 
Ascending Dose-escalation 
Study to Investigate the Safety, 
Tolerability, Pharmacokinetics, 
and Pharmacodynamic Activity 
of MRG-110 Following Local 
Intradermal Injection After Skin 









42 Randomized 1 Completed –
ACE, angiotensin converting enzyme; ASK1, apoptosis signal-regulating kinase 1; DCA, dichloroacetate; ETA, endothelin receptor antagonist; HF, heart failure; HFpEF, 
heart failure with preserved ejection fraction; mPAP, mean pulmonary arterial pressure; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; Nrf2, nuclear  
factor erythroid 2-related factor 2; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; PDK, pyruvate dehydrogenase kinase; PAH,  
pulmonary arterial hypertension; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RHF, right heart failure; RV, right ventricle; RVEF, right ventricular  
ejection fraction; RVAT, right ventricular acceleration time, RVET, right ventricular ejection time.
1748 Klinke et al. Emerging therapies for RV failure
© Cardiovascular Diagnosis and Therapy. All rights reserved. Cardiovasc Diagn Ther 2020;10(5):1735-1767 | http://dx.doi.org/10.21037/cdt-20-592
obtained: β-blockade applied in monocrotaline (MCT) 
and SuHx rat models was associated with reduction of RV 
dysfunction, RV fibrosis and RV inflammation (39-42) 
(Table 1) .  However,  contrasting data suggest that 
reinforcement of β-adrenoceptor signaling improved RV 
function in the MCT rat model (43). Interestingly, agonism 
on the α1A-adrenoceptor prevented and reversed RHF 
in experimental mouse models of bleomycin- and PAB-
induced RV failure (44,45,95) (Table 2). Here, improved 
RV function was linked to increased myofilament force 
development and associated with markedly diminished 
levels of reactive oxygen species (ROS) in the RV.
Modulation of the renin-angiotensin-aldosterone 
system (RAAS)
As it is the case for adrenoceptor blockade, modulation of 
the RAAS is essential in LHF therapy, but its benefit for 
RHF remains elusive. The vasoconstrictive, pro-fibrotic 
and pro-inflammatory properties of angiotensin II (AngII) 
render this pathway attractive also for RHF therapy, and 
in PAH RAAS is clearly activated (46). Nevertheless, in 
experimental studies the AngII type 1 (AT1)-receptor 
blocker losartan had no beneficial effect on the RV (47,49) 
(Table 2). Interestingly, a recent study suggested that the 
combination of AT1-receptor blockade with neprilysin 
inhibition (sacubitril/valsartan), which is successful in LHF 
therapy, improved RV function by attenuating adverse 
myocardial remodeling in PAB-exposed rats (48). Inhibition 
of the angiotensin-converting enzyme (ACE) was rather 
disappointing in small PAH patient cohorts (23,24) (Table 1). 
More promising findings suggest to target ACE2, which 
converts AngI and AngII to Ang 1–7, Ang 1–9 and Ang 1–5, 
exerting vasodilating and anti-inflammatory effects via the 
Mas receptor (96,97). Application of recombinant ACE2 
protein or activation of ACE2 in PAH models reduced PA 
and RV remodeling and improved RV function (51,52). 
Of note, improved RV function was also observed in the 
PAB model, suggesting a direct protective effect on RV 
myocardium (50). The current findings point towards 
the fact that the mechanism of action is rather related 
to anti-inflammatory and anti-oxidative actions than 
directly reducing AngII-dependent effects (98) (Figure 1). 
However, a single intravenous dose of ACE2 in PAH 
patients reduced pulmonary vascular resistance (PVR) 
and increased cardiac output (CO) (31). A phase 2 clinical 
trial proved good tolerability of recombinant ACE2 in 
patients with acute respiratory distress syndrome (99), and 
another phase 2 trial with PAH patients was completed 
recently (NCT03177603). It needs to be considered that 
ACE2 serves as a receptor for coronavirus SARS-CoV2 
and facilitates cell entry potentially not only to alveolar 
cells, but also to cardiomyocytes (100). ACE2 expression is 
augmented on cardiomyocytes in patients with cardiac disease, 
which might increase risk for cardiac complications associated 
with Coronavirus Disease 2019 (COVID-19) (100). 
Most consistent results are derived from studies on 
mineralocorticoid-receptor blockade, which indicate that 
blocking the aldosterone receptor exerts potent effects 
on PA remodeling. Those are related to a decrease of PA 
fibrosis, increase of nitric oxide (NO) bioavailability and 
inhibition of proliferation of pulmonary artery smooth 
muscle cells (PASMCs), but the RV is not directly affected. 
Thus, PA remodeling and PVR and in some studies also 
RVH were diminished by spironolactone or eplerenone 
in PAH models (53-56). In contrast, no effects on RV 
remodeling or function were observed in PAB models 
(49,56) (Table 2). In a retrospective analysis spironolactone 
improved exercise capacity, brain natriuretic peptide (BNP) 
levels and New York Heart Association (NYHA) class 
in PAH patients (22). Ongoing clinical trials will further 
investigate the therapeutic potential of spironolactone and 
its modulation of vascular dysfunction for PAH patients 
(NCT01712620, NCT03344159) (Table 3).
Metabolic regulators 
Metabolic remodeling is an important component of heart 
failure pathogenesis. As described in more detail by Agrawal 
and colleagues (3), due to reduced oxygen availability but 
also triggered by processes like inflammation and increased 
oxidative stress, substrate flexibility of cardiomyocytes is 
impaired. The mechanisms of metabolic dysregulation 
are not yet fully understood. In healthy myocardium, 
fatty acid oxidation (FAO) serves to about 70% for energy 
generation, and energy yield per molecule is higher than 
from glucose oxidation (GO), but on the other hand 
oxygen consumption is higher per molecule substrate. 
In dysfunctional cardiomyocytes, complete oxidative 
phosphorylation (OXPHOS) all the way through the citrate 
cycle (Krebs cycle) and electron transport chain (ETC, 
for efficient ATP production) is decreased and glycolysis 
is enhanced, resulting in reduced ATP generation (101). 
Pressure-overloaded hearts with pathological hypertrophy 
(RVH or LVH) revert to a fetal transcriptional and 
metabolic program, with increased utilization of glucose 
and reduced oxidative capacity (102). An important driver 
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of the so-called Warburg effect, i.e., predominant glycolysis 
despite the presence of oxygen to generate ATP, is increased 
activity and expression of pyruvate dehydrogenase kinase 
(PDK), which inhibits pyruvate dehydrogenase (PDH). The 
Warburg effect does not only occur in the dysfunctional or 
failing RV (103) but also in the pulmonary vasculature (104), 
with the consequence of increased proliferation of PASMCs 
and fibroblasts. 
PDK inhibition
The PDK inhibitor dichloroacetate (DCA) has successfully 
been employed in preclinical models and patients. 
Improvement of RV function in line with increase in GO 
was shown in PAB and MCT rat models (70) and in a 
large animal model of RV volume overload (73) (Table 2). 
Importantly, the advantageous effects of DCA are not 
only related to improved substrate utilization. It also 
restores the expression of voltage-gated potassium channels 
Kv1.2, Kv1.5, Kv2.1 and Kv4.2 in PASMCs and in RV 
cardiomyocytes. In PASMCs this leads to preserved 
membrane potential and diminished vasoconstriction 
in hypoxia (HOX) (71) and MCT rat models (72). 
Restoration of potassium channel expression also affects RV 
cardiomyocyte repolarization (70). However, it is important 
to note that genetic polymorphisms can influence DCA 
efficacy. This was demonstrated by a recent 4-month open-
label trial with 20 PAH patients. Here, DCA reduced PVR 
and increased exercise capacity, and this effect was more 
pronounced in individuals with absent or low polymorphism 
scores for the proteins sirtuin 3 and uncoupling protein 2, 
which regulate mitochondrial function in a PDK-dependent 
manner (25). 
Partial FAO inhibition
FAO is in reciprocal relationship with GO, thus, partial 
inhibition of FAO is an oxygen-sparing mechanism, 
which renders the partial FAO inhibitors ranolazine and 
trimetazidine useful as anti-anginal drugs. Both have 
successfully been used to treat LHF (105-108), whereas the 
effects of ranolazine are also related to inhibition of late 
sodium current, thereby preventing sodium-dependent 
calcium overload (107). However, preclinical effects of 
trimetazidine and ranolazine in animal models of PAH/
RV dysfunction have been small (74,75,109) (Table 2) and 
the results of the first clinical studies with trimetazidine 
have not been published or were negative (110,111). In 
patients with PAH, ranolazine had no effects in a small 
study (27), but significantly improved exercise capacity and 
RV function in another small PAH study (26) (Table 1). It 
remains elusive whether these effects were attributed to 
metabolic modulation or sodium channel inhibition. Several 
clinical trials for ranolazine in PH particularly focusing on 
RV function are ongoing (NCT02829034, NCT01839110, 
NCT03273387) (Table 3). Importantly, FAO is naturally 
downregulated in dysfunctional myocardium, which amongst 
others leads to lipid accumulation in cardiomyocytes 
with enhanced generation of toxic lipid metabolites 
and reduced ATP yield [for detailed review see (101)]. 
Furthermore, mitochondrial fragmentation occurs in 
response to cellular stress in PAH/RV pressure overload 
and induces a metabolic switch from FAO to GO in the 
heart. Reversing this “FAO-to-GO switch” and restoring 
normal cardiac metabolism are sufficient to preserve LV 
function despite mitochondrial fragmentation (112). The 
latter finding indicates that the switch in energy generation 
in the failing adult ventricle may be maladaptive and likely 
contributes to pathogenesis of heart failure. Thus, we doubt 
that the concept of blocking FAO in RV or LV failure with 
pressure overload improves systolic performance, but may 
even have detrimental effects (102). 
Master regulators of glucose and lipid metabolism
A current approach to address metabolic homeostasis in 
the heart and the pulmonary vasculature is to target the 
peroxisome proliferator-activated receptor gamma (PPARγ), 
which is a key modulator of glucose and lipid metabolism, 
including mitochondrial FAO, as recently reviewed (3,113). 
PPARγ is a transcription factor of the nuclear receptor 
superfamily and is activated by thiazolidinediones (TZDs) 
or endogenous ligands at specific binding sites. Pioglitazone, 
which is approved for therapy of diabetes mellitus type 
2, was demonstrated to have a better safety profile than 
rosiglitazone (114,115). Interestingly, current established 
PAH medications, treprostinil and sildenafil exert their anti-
proliferative effects via PPARγ activation (113). In heart 
failure and PAH, the actions of TZDs can be attributed 
to a variety of mechanisms, however normalization of 
cardiac energy metabolism may be an important element. 
Intriguingly, cardiomyocyte-specific deletion of PPARγ 
in mice provoked LV and RV systolic dysfunction, which 
was accompanied by decreased mRNA expression of genes 
encoding for important mediators of FAO (78). Pioglitazone 
inhibited exaggerated RV glucose uptake in SuHx-treated 
rats and reduced RV intramyocardial lipid accumulation as a 
possible culprit for lipotoxicity and RV failure. Pioglitazone 
further prevented RV fibrosis and normalized RV 
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cardiomyocyte mitochondrial structure and organization. 
This, together with attenuated PA remodeling accounted 
for marked reduction of RVH and normalization of RV 
function (Table 2, Figure 1). Interestingly, transcription of 
important FAO-regulating genes, including PPARγ itself, 
proved to be downregulated in RV cardiomyocytes of PAH 
patients and were upregulated by pioglitazone in isolated 
neonatal cardiomyocytes (78). Besides this robust signal 
for the therapeutic action of TZDs via a direct effect on 
myocardial energy metabolism, a variety of other studies 
identified beneficial effects in preclinical PAH models linked 
to anti-inflammatory, anti-proliferative, pro-apoptotic and 
vasodilatory effects. Deletion of PPARγ in SMCs led to the 
development of PAH in mice. It was unraveled that PPARγ 
is a downstream target of bone morphogenetic protein 
(BMP) receptor type-2 (BMPR2), which mediates inhibition 
of SMC proliferation (116). Several further studies 
demonstrated TZD-dependent benefits in experimental 
PAH due to attenuation of PA vasoconstriction and 
remodeling (79-81,117). Importantly, since FAO also 
increases oxygen consumption while producing more ATP, 
therapeutic PPARγ activation may require sufficient oxygen 
supply to the myocardium. Thus, PPARγ activating agents 
may not be started in end-stage PAH with low CO and 
high end-diastolic ventricular filling pressures. In these 
situations, the failing RV may incrementally benefit from 
oxygen sparing therapeutic approaches at the expense of 
less efficient ATP production. Despite the robust evidence 
provided by preclinical studies, there are no ongoing clinical 
trials to investigate TZDs for RHF or PAH.
Metformin 
Enhanced lipid accumulation has been detected in human 
RV tissue of patients (postmortem) and in mice with 
heritable PAH (76). In this study, lipid accumulation in the 
BMPR2 R899X transgenic mouse model of PAH could 
be diminished by application of the biguanide metformin, 
however RV function was not improved. Metformin 
impacts on energy metabolism via activation of 5'-adenosine 
monophosphate-activated protein kinase (AMPK). RV lipid 
accumulation was also reduced by metformin in a model 
of metabolic syndrome induced by Western diet, in which 
RV dysfunction was further exaggerated by PAB (77). 
Metformin reduced RVH and improved RV diastolic 
function. Other experimental studies related positive 
effects of metformin on the RV to alternative mechanisms. 
In HOX and MCT rat models, metformin reduced PA 
remodeling, which was due to stimulating endothelial NO 
synthase activity and inhibiting mitogen-activated protein 
kinases (MAPK) (118). Moreover, in the SuHx rat model 
attenuated PA remodeling was linked to an inhibition of 
aromatase transcription, resulting in decreased estrogen 
levels (119). A phase 2 clinical trial investigates the effect of 
metformin in PAH (NCT03617458) and HFpEF-associated 
PH (NCT03629340). 
Taken together, metabolic dysregulation in right heart 
dysfunction and failure is a promising therapeutic target. 
Further studies to understand its significance for PAH 
and RHF, to unravel in particular the role of FAO in RV 
failure, and to find appropriate, safe and efficient drugs are 
indispensable.
Inhibition of inflammation and oxidative stress
Inflammation has been suggested as a mediator and 
potential therapeutic target in cardiovascular disease (CVD), 
however no anti-inflammatory therapy has been approved 
yet. The mostly low-grade and sterile inflammatory 
processes in CVD comprise activation of leukocytes and 
fibroblasts with release of cytokines and ROS. Recent 
results from the CANTOS trial have shown that anti-
inflammatory treatment using a neutralizing antibody to 
interleukin (IL)-1β reduced hospitalization for LHF (120). 
In patients with PAH, levels of circulating inflammatory 
markers correlate with disease severity, symptom burden 
and survival (121-125). The majority of studies investigating 
the role of inflammation in PAH links it to adverse 
pulmonary vascular remodeling (62,125,126). In contrast, 
the effects of inflammation and anti-inflammatory therapy 
on RV remodeling and function are less clear. It is known 
that modulated apoptosis, increased reactive fibrosis, 
disturbed metabolism with mitochondrial dysfunction, 
altered Ca2+ handling and dysintegrity of sarcomere proteins 
are sensitive to inflammation and ROS (126-128). A number 
of experimental studies investigating RV remodeling and 
dysfunction following PAB have described increased RV 
cytokine levels and/or leukocyte infiltration (125). Thus, 
anti-inflammatory and anti-oxidative therapy is a promising 
tool to target PA and RV remodeling (129). 
Blockade of cytokines and leukocyte enzymes
One potential strategy is blocking certain cytokines or their 
receptors. Cytokines like IL-1β, IL-6 and tumor necrosis 
factor-α (TNF-α) are not only released in models of and 
patients with PAH, but their tissue levels also increased in 
RV myocardium following PAB in mice (130). IL-1β is a 
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central mediator of the inflammasome, however antagonism 
of the IL-1 receptor by anakinra yielded inconsistent results 
in preclinical and clinical studies. Its administration to 
MCT-treated rats reduced PA remodeling, however it failed 
to exert any effects in the HOX model of PAH as tested 
in the same study (69) (Table 2). It has to be considered 
that IL-1β regulates transdifferentiation of fibroblasts 
to activated myofibroblasts and may attenuate fibrotic 
remodeling (131-133). In a recent small single-arm open 
label PAH study, 14 days treatment with anakinra reduced 
C-reactive protein levels and symptom burden, but RV 
function was not significantly changed (29) (Table 1). 
TNF-α inhibition appears to exert effects on PA 
remodeling. The specific antagonist etanercept modified PA 
remodeling and reduced PA pressure in experimental PAH 
models (66,67). 
The IL-6 receptor (IL-6R) is another potential 
therapeutic target in PAH. IL-6R on the surface of PASMC 
serves as a survival factor, and IL-6R antagonism not only 
reduced PA remodeling but improved RV function in 
MCT and SuHx rat models (68). However, the monoclonal 
antibody tocilizumab failed to achieve a change in PVR 
in a phase 2 open-label proof-of-concept study with PAH 
patients (28).
An important source of ROS is the leukocyte enzyme 
myeloperoxidase (MPO), that has been linked to a variety of 
cardiovascular conditions (134). MPO levels were increased 
in lungs of PAH patients. Knockout or inhibition of MPO 
reduced RVH, PA pressure and remodeling in the MCT rat 
and HOX mouse PAH models (62).
Targeting signaling mediators
A promising concept is to target central intracellular 
signaling cascades. The transcription factor nuclear factor 
E2-related factor 2 (Nrf2) induces anti-oxidative effects 
like increased expression of heme-oxygenase-1 (HO-1). 
HO-1- as well as Nrf2-deficient mice develop RV dilation 
and infarction or PA remodeling and RVH, respectively, 
under hypoxic conditions (58,135). Stimulation of Nrf2 and 
HO-1 expression with Protandim in the SuHx rat model 
of PAH attenuated RV fibrosis and capillary rarefaction 
and improved RV function, without changes in PA pressure 
or remodeling (136). Nrf2 stimulation with oltipraz 
showed protective effects on PA remodeling in the HOX 
mouse model (58). Nitro-fatty acids (NO2-FA), a group 
of molecules with anti-inflammatory and anti-oxidative 
properties, in part via induction of HO-1 expression (137), 
attenuated PA remodeling, RVH and fibrosis in the HOX 
mouse model (61). A current phase 2 multicenter clinical study 
explores NO2-FA in patients with PAH (NCT03449524). 
Other Nrf2-stimulating agents (dimethyl fumarate), a 
superoxide dismutase (SOD) mimetic, and the PPARγ receptor 
stimulator rosiglitazone all exert anti-oxidative effects and 
achieved benefit in preclinical PAH models (57,59,60) 
(Table 2). The Nrf2 and HO-1 axis is thus a promising target 
to reinforce anti-inflammatory and anti-oxidative processes 
(Figure 1). The Nrf2 activator bardoxolone methyl significantly 
improved exercise capacity in PAH patients in a phase 
2 trial (138) (NCT02036970), although it was associated 
with adverse cardiovascular events in patients with end stage 
chronic kidney disease. Two more clinical trials are ongoing 
(NCT03068130; NCT02657356) (Table 3). 
Furthermore, studies demonstrating inhibition of toll-
like receptor 9/nuclear factor kappa-light-chain-enhancer 
of activated B-cells (NF-κB) signaling (63) and inhibition of 
apoptosis signal-regulating kinase (ASK)1 and p38 MAPK 
activity in PAB models (64,65) are in favor of blocking 
inflammatory pathways. However, a clinical study on ASK1 
inhibition in PAH including 150 patients failed to reach its 
primary endpoint (NCT02234141) (30).
Overall, modulation of inflammation and oxidative stress 
is a promising strategy to target maladaptive RV remodeling 
as well as PA constriction and remodeling in PAH at the 
same time. Given that a certain level of ROS is required 
for adaptive cell signaling and homeostasis, and that 
inflammatory cascades are indispensable for intact immune 
defense, induction of anti-oxidative and anti-inflammatory 
cascades may be the most prospective and feasible concept. 
Modulation of extracellular matrix (ECM) remodeling 
Fibrotic remodeling with enhanced deposition of interstitial 
and perivascular collagen and transdifferentiation of 
fibroblasts to myofibroblasts is a hallmark of the pressure 
overloaded and dysfunctional RV. Fibrosis also occurs 
during adaptive remodeling, but is suggested to become 
maladaptive when the stressor like increased afterload 
persists. It leads to increased ventricular stiffness and 
susceptibility to arrhythmias. It is widely accepted that 
maladaptive fibrosis of the LV contributes to impaired 
systolic and diastolic function and is associated with 
increased morbidity and mortality (139). This is, however, 
less clear for the RV. Preclinical studies suggest that 
effective therapeutic approaches to alleviate PAH or RV 
dysfunction upon PAB most commonly go along with 
a reduction of RV fibrosis (140). In the PAB model this 
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was the case with a p38MAPK inhibitor (65), a 5-HT2 
receptor antagonist (141), the prostacyclin analogue 
iloprost (35), the antioxidant protandim (136) and an ASK1 
inhibitor (64). p38MAPK and ASK1 inhibition attenuated 
cardiac fibroblast activation and improved RV systolic 
function. However, recent research has challenged the 
concept of a causal relationship between fibrosis and RV 
function. A recent study by Boehm and colleagues showed 
that in a reversible PAB mouse model RV fibrosis slowly 
reversed at a time point when RV function and hypertrophy 
were already fully normalized (142). A promising biomarker 
and therapeutic target for cardiac fibrosis is galectin-3, 
which was linked to the development of LHF and also 
mortality and RV dysfunction in patients with PAH (83). In 
the murine PAB model, galectin-3 knockout or inhibition 
and also the anti-fibrotic agent pirfenidone attenuated RV 
fibrosis, but did not significantly affect RV function (83).
HDAC inhibitors
There is growing interest in epigenetic mechanisms in 
CVD. An important element of epigenetic regulation is 
histone acetylation, controlled by histone acyltransferases 
and histone deacetylases (HDACs), which influences cell 
proliferation and survival. Pan-HDAC and selective HDAC 
inhibitors have been employed in PAH and RV pressure 
overload models, yet with inconsistent results. Several 
studies have observed reduced PA remodeling, and with 
this reduced PA pressure, PVR and RVH in different PAH 
models (84,85,87,89) (Table 2). One study could not detect 
any improvement of PA or RV remodeling in the SuHx 
rat model (88). In PAB-exposed rats, HDAC inhibition 
even had detrimental effects on RV function (86). These 
discrepancies might be related to the fact that HDAC 
activation is substantially different in the pulmonary 
circulation in different PAH models, and is further different 
between lung and RV (88). The potential anti-angiogenic 
and pro-apoptotic effects of HDAC inhibition, which 
may be beneficial in PA remodeling in PAH, could exert 
detrimental effects on the RV myocardium (88).
Approaches specifically addressing PA remodeling in PAH
A number of therapeutic approaches that clearly target 
PAH-specific mechanisms of PA remodeling are under 
investigation, and have been extensively reviewed elsewhere 
(110,113,143-146).
The pulmonary vasculature in PAH presents with a 
distinct phenotype of hyperproliferation, resistance to 
apoptosis and activation of specific signaling pathways (146). 
Current research focuses on a variety of molecules, 
with ambiguous results regarding the RV. For example, 
oncologic drugs have been evaluated for PAH therapy. 
Imatinib is a tyrosine kinase inhibitor that targets, amongst 
others, platelet-derived growth factor receptor (PDGFR) 
signaling, which importantly contributes to maladaptive 
PA remodeling in PAH. Imatinib impressively reversed 
pathological remodeling in experimental PAH (82). 
However, given that PDGF exerts positive effects on the 
myocardial level, e.g., mediates adaptive remodeling upon 
pressure overload (147,148), the net benefit of imatinib 
on RHF in PAH remains elusive. Moreover, serious 
adverse events were observed in clinical studies, which 
resulted in termination of a recent trial (NCT01117987). 
Still, given promising results from investigations of PAH 
patients (32,33), tyrosine kinase inhibition is under new 
clinical investigation in the UK (“Positioning Imatinib for 
Pulmonary Arterial Hypertension”; NIHR128465).
Modulation of the bone morphogenetic signaling in 
the pulmonary vasculature, and possibly also in the RV, is 
currently a “hot topic” in the field of PH (116,149): Calvier 
et al. identified PPARγ as the missing link that regulates the 
complex balance between mitogenic, glucose metabolism-
promoting transforming growth factor (TGF)-β1 signals 
and vasoprotective BMP2/BMPR2 in vascular SMC (150). 
Several comprehensive studies aimed at either restoring 
BMPR2 expression and function using FK506 (151,152), 
or rebalancing TGF-β/BMP signaling using the PPARγ 
agonist pioglitazone (78,150,153) or ACTRIIA-Fc 
(sotatercept) which had therapeutic effects both at the 
preclinical (154) and clinical levels (NCT03738150). In 
addition, SMAD-specific E3 ubiquitin protein ligase 1 
(SMURF1) has been identified as a critical regulator of 
BMP signaling, given that SMURF1 blood levels were 
increased in PAH patients and SMURF1-deficient mice 
were protected from PAH in the SuHx model (155). 
Early clinical studies of BMP-modulating therapies in 
patients with PAH provide positive proof of concept and 
the development of novel therapies in the area offers the 
promise of future patient benefit (sotatercept PULSAR 




Several key structural and molecular differences have 
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been identified in both preclinical and clinical studies that 
distinguish between adaptive and maladaptive pathways 
for RV remodeling. Although the mechanisms underlying 
the shift from an adaptive to maladaptive phenotype are 
only beginning to be understood, it is clear that metabolic 
and neurohormonal dysfunction, capillary rarefaction, and 
profibrotic pathways are emerging as important elements (3). 
In particular, reduced microvascular density is thought to be 
a harbinger of maladaptive remodeling, and a leading cause 
of RHF in PAH patients (143,156). RV biopsies from PAH 
patients with RHF show reduced microvascular density, as 
well as downregulation of angiogenic genes such as, VEGF 
and Ang-1 (157,158). This suggests that the intrinsic link 
between microvascular rarefaction and pathological RV 
remodelling may drive the progression of RV failure in 
some patients that could be treated with angiogenic cell 
therapies. Indeed, stem cell therapies with pro-angiogenic 
properties targeted towards the RV may represent a novel 
therapeutic avenue to improve its function. 
The RV may represent an excellent target for cell-
based therapies given its tremendous plasticity and capacity 
to reverse remodeling when the afterload is removed. 
However, to date, most cell therapy studies have targeted 
the pulmonary circulation, though some of the benefits 
may be attributable to effects of the therapy on the RV. 
Mesenchymal stem cells (MSCs), endothelial progenitor 
cells (EPCs), and cardiac progenitor cells (CPCs) have 
all demonstrated efficacy in reducing RV systolic pressure 
(RVSP) and RV remodeling in animal models of PAH (159). 
Many of these studies also noted ancillary beneficial effects 
on RV function; however, it is not possible to discern 
whether cell therapy had a direct benefit on the RV or 
whether any improvements occurred merely as a result of 
afterload reduction. For this reason, a model system that is 
not affected by confounding influences from effects on the 
pulmonary vasculature, such as the PAB model, is needed in 
order to provide convincing evidence for a direct effect of 
cell therapy on the RV. 
Moreover, these studies used intravenous, intrajugular, or 
intratracheal routes of administration that favours targeting 
of cells to the lung vasculature, and it is not known to what 
extent (if any) cells would be delivered to the RV. Indeed, 
studies of cell therapies targeted to the LV have revealed 
poor cell engraftment after intravenous delivery (160). 
However, this does not exclude the possibility of an 
indirect paracrine effect following the delivery of stem/
progenitor cells or cell-derived extracellular components 
[e.g., extracellular vesicles (EVs), miRNA]; for example, 
a reduction in inflammatory mediators, which could 
beneficially effect RV remodeling. Nonetheless, for a cell-
based therapy to have maximal impact on RV function, 
local delivery of stem cells either by intramyocardial or 
intracoronary injection, would likely be preferable. Table 4 
summarizes preclinical studies that have used models 
with a relatively fixed RV afterload (i.e., PAB or chronic 
thromboembolic models) to assess the effects of targeted 
RV delivery of CPCs, EPCs, mononuclear cells (MNCs), 
or MSCs on RV structure and function. It is encouraging 
that all these studies demonstrated improved RV function 
associated in many cases with increased RV capillary 
density, decreased RV fibrosis and RVH, as summarized in 
this table. 
Although cl inical  tr ia ls  target ing the LV have 
demonstrated that stem cell delivery via transcoronary, 
transatrial, intramyocardial and intravenous delivery 
is safe and feasible, they have produced mixed results 
regarding efficacy. There is more limited literature of 
targeted RV clinical cell therapy trials, and much of the 
available human evidence for RV targeted therapy comes 
from pediatric patients with CHD (10). The TICAP 
(Transcoronary Infusion of Cardiac Progenitor cells) phase 
1 trial evaluated the safety of autologous cardiosphere-
derived cells (CDC) in children with hypoplastic left 
heart syndrome (systemic RV) (165). In these patients, 
intracoronary CDC administration was safe and improved 
RVEF and clinical status as compared to patients that 
received standard therapy. The efficacy of CDC therapy 
for this patient population was recently confirmed in the 
phase 2 PERSEUS trial (Cardiac Progenitor Cell Infusion 
to Treat Univentricular Heart Disease) (166). Results 
demonstrate that CDCs markedly improve RV function 
(RVEF, 3 months ↑6.4%, 12 months ↑7.4%) and heart 
failure status and mitigate cardiac fibrosis. Moreover, in 
a preclinical PAB model, intramyocardial administration 
of CPCs improved RV contractile function, increased RV 
microvascular density, and reduced RVH and fibrosis (161). 
The study further demonstrated that the proangiogenic and 
antifibrotic actions of CPCs were mediated by exosomes 
(CD9+, 96.1±6.1 nm). A phase 1 study (ALPHA trial: 
NCT03145298) is currently evaluating the safety and 
feasibility of intravenous delivery of allogeneic human CDC 
in patients with PAH. In this trial, an exploratory endpoint 
is evaluating the effect of cell therapy on RV function and 
pulmonary hemodynamics. Two other trials are currently 
ongoing assessing the safety and efficacy of adipose-
derived MSC (NCT04055415), and eNOS-enhanced 
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Table 4 Preclinical studies evaluating the efficacy of RV targeted cell therapy
Studies Model Cell type Delivery RV benefit
Trac et al., 2019 (161) Rat PAB CPC RV intramyocardial ↑RV systolic function
↑RV capillary density
↓RV fibrosis




Loisel et al., 2019 Swine CTEPH  
Model
EPC RCA infusion ↑RV Systolic function
↓RVH
↑RV capillary density
Oommen et al., 2015 Mice PAB UCB-MNCs RV intramyocardial ↑RV systolic function
↑RV capillary density
↓RV fibrosis
Chery et al., 2019 (163) Rat PAB Nt-MSCs Sheet scaffold application  





Liufu et al., 2020 (164) Mice PAB BMSCs RV intramyocardial ↓RVH
↑RV capillary density
↓RV fibrosis
Davies et al., 2010 Sheep PAB CBSC Epicardial injection ↑RV systolic and diastolic function
CBSC, cord blood stem cell; PAB, pulmonary artery banding; CTEPH, chronic thromboembolic pulmonary hypertension; BMSCs, bone 
marrow derived MSC; UCB, umbilical cord blood; Nt-MSCs, neonatal thymus MSC. 
EPCs (SAPPHIRE, NCT03001414) in patients with PAH. 
While these studies are targeting the lung vasculature by 
delivering cells intravenously, RV structure and function 
will be assessed as a secondary endpoint. 
Several recent studies have explored the intravenous 
effect of MSC-derived EVs, on PA remodeling, RVH 
and pressure, in rodent models of PAH, such as SuHx rat 
(167,168) and MCT rat (169). Others have investigated the 
effect of intravenous delivery of EVs for treatment of PH 
associated with bronchopulmonary dysplasia (170), and a 
clinical trial is underway (NCT03857841). However, as 
mentioned above no direct effect on the hypertensive RV 
can be demonstrated in these studies due to the animal 
models used.
To our knowledge, no human trial  is  currently 
assessing the impact of intramyocardial or intracoronary 
administration of stem cells  or stem-cell  derived 
components (e.g., EVs) in patients with PAH and RV 
failure. This relatively unexplored therapeutic avenue 
may have tremendous potential as RV function is a critical 
determinant of prognosis, with RV failure representing 
the leading cause of death in these patients (1). The 
accumulating preclinical evidence seems to suggest a direct 
and robust RV benefit, providing a strong rationale for 
future translation to human trials.
Non-approved RNA-based therapies
 
Noncoding RNAs, including microRNA (miRNA), long 
non-coding RNA (lncRNA), circular RNA (circRNA), and 
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Y RNAs in CVD have been comprehensively reviewed 
elsewhere (171-173). Although non-coding RNA-based 
therapy in LHF has received significant attention in both 
preclinical models and, to a lesser degree, in clinical trials 
(NCT04045405; NCT03603431) (173), its therapeutic 
potential in RV failure remains largely unexplored. 
At the molecular level RV remodeling is characterized 
by a return to a fetal-like pattern of energy substrate 
metabolism, enhanced inflammation and ischemia due 
to capillary rarefaction (174) promoting the loss of 
cardiomyocytes and the appearance of pronounced interstitial 
and perivascular collagen deposition (fibrosis) (175). 
With the technological advances of “omics”, numerous 
studies have linked these changes to the altered expression 
of many non-coding RNAs including lncRNAs, miRNAs 
and circRNAs (176-178), but so far only few miRNAs have 
been therapeutically investigated directly in the RV. 
miRNA-based therapies for PAH-associated RV 
dysfunction
Although in vivo modulation of miRNA expression levels 
is challenging (179), the development of synthetic small 
duplex RNA designed to specifically inhibit (AntimiR) or 
supplement (mimics) endogenous miRNAs now represents 
a promising approach to treat various disorders. This 
approach has been extensively explored in animal models of 
PH to prevent or reverse pulmonary vascular remodeling 
(180-183), and most of the studies showed improvement 
in PH and in RV function. However, to the best of our 
knowledge, only the role of miR-126 (158), miR-208 (184), 
and miR-223 (185) have been investigated in RV failure 
independently of the effects on the lungs. miR-126 is known 
as an angiogenesis-regulating miRNA. It is one of the few 
EC-specific miRNAs, and regulates vascular integrity and 
developmental angiogenesis. miR-126 was downregulated in 
both the failing human and rat RV and negatively correlated 
with disease severity. Its enforced expression in vivo using 
mimics improved RV function by increasing vascular 
density and reducing fibrosis (158). Along with miR-126, 
the muscle-specific miRNA miR-208a was also decreased 
during RV decompensation. Its diminution associated 
with the rise in TNF-mediated inflammatory response 
was suggested to indirectly repress the transcription factor 
MEF-2, thus promoting entrance into a decompensated 
phase (184). Finally, miR-223 is known to be downregulated 
in many hyperproliferative diseases like cancer and PH, but 
has also profound effects on RV function independent of 
its function in the lung. miR-223 overexpression targeting 
cardiomyocytes improved CO in animals exposed to 
HOX, whereas its downregulation in rats subjected to 
PAB elicited opposite effects (185). Despite the fact that 
RV-based research remains the Cinderella area of most 
PH research, several new treatments exhibiting important 
RV improvement in PH models have been preclinically 
identified and are now under clinical investigation (144). 
Although for most of the new (experimental and approved) 
therapies effects on non-coding RNA signaling remains 
unknown, some of these treatments have clearly shown 
their ability to regulate non-coding RNA expression. 
For example, PPARγ activation by pioglitazone fully 
reversed PH and prevented RV failure, as mentioned 
above. The restoration of disturbed lipid metabolism and 
mitochondrial morphology/function led to normalization 
of the expression of several miRNAs (78). Consistently, 
pre-miRs-197 and -146b greatly repressed genes that drive 
FAO (Cpt1b, Fabp4) in cultured primary cardiomyocytes. 
Importantly, these major pathogenic findings in SuHx rats 
were recapitulated in human end-stage PAH, i.e., miR-197 
and miR-146b were upregulated in the pressure-overloaded 
failing RV (78). A clinical trial was launched on the use for 
pioglitazone in PAH (NCT00825266) but was terminated 
due to difficulties in recruitment, probably because of 
insulin resistance being a mandatory inclusion criterion.
In human PASMC, the BMP2/BMPR2-PPARγ axis 
upregulated miR-148a and miR-331-5p, thereby inhibiting 
SMC proliferation and glucose metabolism (150,153). 
miR-331-5p downregulated the platelet isoform of 
phosphofructokinase (PFKP) messenger RNA (150), a 
rate limiting enzyme of glycolysis and, as such, a pro-
proliferative factor that is overexpressed in situ in the 
pulmonary arteries of patients with idiopathic PAH. 
However, neither the aforementioned axis nor downstream 
miRNA have been studied systematically in the hypertensive 
RV or cultured cardiomyocytes.
LncRNA-based therapies for RHF
It has been demonstrated recently, that the lncRNA H19 
is causally involved in pathological RV remodeling and 
has a predictive value (186). Silencing H19 reduced RV 
remodeling and improved RV function in MCT and PAB 
rat models. In PAH patients it was upregulated particularly 
in decompensated RV, and circulating H19 levels predicted 
survival in PAH patients (186). Whereas these findings 
identify H19 as a promising therapeutic target, they at 
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the same time underscore the fundamental differences 
between the LV and RV, given that H19 has been shown 
to be downregulated in failing LV and that gene therapy 
augmenting cardiac H19 levels reversed pressure-induced 
LHF (187). 
PA denervation
Patients with PAH show signs of sympathetic overdrive (188) 
that is associated with adverse clinical outcomes (189). 
Lungs and pulmonary vasculature contribute to circulating 
catecholamine levels (190) and are one of the major sites of 
ACE expression and AngII production. Modulation of the 
sympathetic and renin-angiotensin-aldosterone systems is 
an established treatment for heart failure. Both β-blockers 
and ACE inhibitors have been shown to attenuate disease 
in experimental models (40,42,191), however, there is no 
evidence of benefit in patients with PAH (20,192,193). 
Targeted, catheter-based, renal denervation reduces blood 
pressure in patients with systemic hypertension both on or 
off anti-hypertensive therapy (194-196). The development 
of such technologies offers the opportunity to modulate 
sympathetic activity through targeted denervation of the 
pulmonary vasculature, potentially avoiding the adverse 
effects of systemically active therapies.
Sympathetic and parasympathetic nerves derived 
from the spinal ganglions (sympathetic) and vagus nerve 
(parasympathetic) merge to form the pulmonary plexus, 
which was larger around the main PA (197). Running 
with the pulmonary vasculature, nerves branch, reducing 
in size after the bifurcation of the main PA forming a 
circumferential network around the vessels before the 
hilum of the lungs. Preclinical studies have demonstrated 
that pulmonary artery denervation (PDN) improves 
pulmonary haemodynamics in acute (198,199) and chronic 
models of PH (200). The application of radiofrequency 
energy, which induces long-term alterations in nerve 
conduction, to a specific location at the bifurcation 
i s  reported to  provide  an acute  improvement  in 
hemodynamic status that persists to 3 months despite 
the withdrawal of disease-specific therapy in patients 
with PAH (201). Early indicators of efficacy have also 
been reported in patients with chronic thromboembolic 
pulmonary hypertension (CTEPH) and left heart disease 
associated PH (202,203).
Current European guidelines indicate that patients 
with PAH and high-risk features should be treated with 
two disease-specific therapies (204). Using an alternative 
catheter-based ultrasound denervation procedure (197) 
the recent TROPHY study enrolled 23 patients with PAH 
established on a minimum of dual oral therapy (205). Four 
to 6 months following ultrasound PDN, PVR was reduced 
by 94 dyn·s·cm−5 and 6-minute walking distance (6MWD) 
increased by 42 m, a result that is congruent with a 
minimally important clinical difference of 33 m (206). The 
observed increase in daily activity and improved clinical 
risk score further indicate a potential benefit of this novel 
therapy, on a background of guideline-directed medical 
therapy.
Further studies are required to evaluate efficacy, safety, 
and clinical impact of PDN in patients with PAH and other 
forms of pulmonary hypertension.
Mechanical circulatory support (MCS)
In contrast to MCS for LHF, MCS for RHF is still in 
its early stages and experience is, with a few exceptions, 
limited to case reports and series. Indications comprise 
acute myocardial infarction, pulmonary embolism, post-
cardiac surgery, post heart transplantation, myocarditis 
as well as decompensated chronic heart failure and thus 
mostly involve concomitant left ventricular disease. A 
special indication is RHF after LVAD implantation. It is 
important to differentiate between acute MCS and efforts 
to achieve durable results. In general, RHF may be bridged 
by bypassing the RV [right atrium (RA) to PA] or the RV 
and LV [RA to aorta (AO)], and there is considerable debate 
which approach should be used in different conditions. 
Most centers prefer a bypass of both ventricles in conditions 
where pulmonary resistance is elevated by the condition, 
such as pulmonary hypertension or pulmonary embolism. 
In contrast, a pure RV bypass is usually employed when RV 
failure results from a cardiac cause, such as RV myocardial 
infarction.
Acute MCS
The percutaneous Impella RP microaxial pump is 
introduced via the femoral vein and transports blood 
from the RA to the PA via an impeller. It has no option to 
oxygenate blood. The Tandem Heart right ventricular assist 
device (RVAD) requires two femoral vein cannulations, 
one for the draining cannula placed in the RA and one 
for the outflow cannula placed in the PA. Cannulation 
of right jugular vein is used in some cases. Additional 
oxygenation and carbon dioxide removal is possible with 
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this system. The same configuration can be built with 
standard extracorporeal membrane oxygenation (ECMO) 
machines, using a femoral venous draining cannula and 
a flexible supply cannula, which is inserted through the 
jugular vein and the RV to the PA (207). The Protek Duo 
dual-lumen cannula, which is also commonly inserted via 
the jugular vein, combines right artery draining and PA 
outflow in one cannula. Veno-arterial ECMO (V-A ECMO) 
differs from the previous systems in that it delivers blood 
from the RA via an oxygenator to the arterial circulation. 
As a consequence, these systems increase left ventricular 
afterload, thereby promoting pulmonary edema particularly 
in the presence of left ventricular dysfunction. The most 
important characteristics of the described systems are 
summarized in Table 5.
Durable MCS 
Durable MCS devices were formerly implanted as bridge-
to-transplantation. Recently, durable MCS is more 
frequently employed as destination therapy, given the 
shortage of donor hearts. In addition, it is used as bridge-
to-decision, i.e., in instances where support is required 
for prolonged time intervals. All systems require surgical 
implantation and can be divided into those employing 
extracorporeal pumps (Berlin Heart Excor, Total artificial 
heart) and fully implantable systems. For the former, in-
hospital treatment is mandatory because of their set-up 
and the intense supervision required. The latter mostly 
comprise LVAD connected to the RA (draining) and PA 
(outflow), with implantation techniques increasingly being 






Impella RP RA PA 14 d n=30 (18 LVAD, 12 post-cardiac surgery), 30 d survival 73% (recover right) 
(208)
Tandem Heart RA PA 4 d n=46 (18 post-cardiac surgery, 12 myocardial infarction, 5 LVAD, 5 post 
HTX), in-hospital mortality 57% (209)
V-Pa ECMO RA PA 30 d Restricted to case series
V-A ECMO RA FA 30 d n=179 (70 post-cardiac surgery, 46 myocardial infarction), in-hospital mor-
tality 39% (210)
CentriMag RA PA 30 d n=38 (14 myocardial infarction, 12 LVAD, 12 post-cardiac surgery), mean 
duration of support 13 d (1–60 d), in-hospital mortality 58%, 30 d (211)
Durable MCS
Berlin Heart RA PA – Mostly children, restricted to case series
Heart Ware/
Heart Mate 3
RV PA – Heart Ware (meta-analysis): n=56 (85% non-ischemic cardiomyopathy), 
30-day mortality 9%, time on device 156 (IQR, 66–351), heart  
transplantation 46% (212)
Heart Mate 3: n=14 (50% DCM; 28% ICM), 9 patients died within 6 
months, 1 successful heart transplantation, 8 patients continuing support 
for 266 (95–636 days) (213)
Total artificial 
heart*
RA PA (requires RV 
explantation)
– n=450 (50% DCM, 20% ICM), 266 underwent heart transplantation, 
12-month survival 53% (214) 
BiVACOR* Requires native cardiectomy – Pre-clinical
RealHeart* Requires native cardiectomy – Pre-clinical
Carmat* Requires native cardiectomy – Early feasibility trial approved
*, biventricular support devices. DCM, dilated cardiomyopathy; ECMO, extracorporeal membrane oxygenation; FA, femoral artery; ICM, 
ischemic cardiomyopathy; LVAD, left ventricular assist device; PA, pulmonary artery; RA, right atrium; RV, right ventricle; V-A, veno-arterial; 
V-Pa, veno-pulmonary arterial.
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adapted and smaller systems emerging which might be 
better suitable for RV support. Evidence for all of these 
systems is restricted to case examples.
Conclusion and perspective 
Despite remarkable advancements in PAH therapy during 
the last decade, PAH-related mortality, especially from RV 
failure, remains high. It is a matter of debate whether PAH 
patients will substantially benefit from therapies directly 
targeting the RV myocardium. Particularly promising, 
novel therapeutic targets in RHF include RV metabolic 
imbalance, inflammation and oxidative stress. 
Besides pharmacological therapies (be it “repurposed” 
or newly developed), cell and RNA-based therapies have 
generated substantial recognition, due to solid preclinical 
and early clinical study results. Discrepant mechanistic 
profiles in different pre-clinical models and contrasting 
pathomechanisms in the pulmonary vasculature and 
RV myocardium in PAH complicate the development 
of effective therapeutics. Further experimental research 
and clinical studies are required to successfully advance 
therapeutic options for PAH and RV failure.
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